Thanks for posting this Saltz, in our experience with Nader, he either is so optimistic he says more than he should or he says nothing because he has been told to keep quiet. The tone from this response tells me is is as perterdaniels' opinion that it is business as usual. I don't think that is a bad thing, reading the 10q tells us where they are at and it looks like the positive PR's needed to support the uplisted stock are not there yet.
The one thing that is really obvious is that mgmt is not skilled in managing a publicly traded stock - not that they should be, just that this is not their forte. I think there are a lot of opinions coming from investors about how they should manage the SP and some likely pushed for the R/S and uplisting and some voiced the opinion that is a bad idea. uplisting might give them the SP response to good news that the OTC can't but also might allow shorts to rule the day. My opinion goes either way, treating this as a private investment and staying on the OTC does provide some level of protection but on the other hand the exposure to a large market could provide the valuation to move to a better (higher) level. At the end of the day they are developing a product that should be bought by a large company that can finish it and market it. Weather it is on the OTC, private or on the nasdaq does not matter when that deal happens. I would think the ability to raise capital might be the motivation to be on the bigger market - investors want the ability to sell their shares, the OTC is not the best for that (as we all know).
I am of the opinion that there is no near future buy out in the works, I think they were looking for a better way to raise cash and found it without having to go through the cost of uplisting. Could it be a partnership in the GvHD indication?
News 
Market Data 
Discover 
AI
